Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Albumin-bound docetaxel versus placebo with best supportive care in previously treated advanced pancreatic cancer
CTR20242306Phase 3Active
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology
- Start
- Jul 2024
- Modality
- Small Molecules, Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
A Phase 3 trial of albumin-bound docetaxel in pancreatic cancer (PC), pancreatic adenocarcinoma (PDAC), sponsored by CSPC ZhongQi Pharmaceutical Technology. Started Jul 2024; status: active.
02
Drugs
albumin-bound docetaxel
03
Conditions
pancreatic cancer (PC)pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on CTR20242306.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20242306.